The Hindu·2 min read·medium
Cipla receives U.S. FDA approval for generic of asthma, COPD drug
T
The Hindu Bureau
✦AI Summary
Cipla has received U.S. FDA approval for a generic version of the asthma and COPD medication Advair Diskus. The company plans to launch the product in the U.S. market by the second quarter of fiscal year 2027.
Cipla has received approval from the U.S. Food and Drug Administration (U.S. FDA) for its abbreviated new drug application (ANDA) for generic Advair Diskus (fluticasone propionate and salmeterol inhalation powder) in three strengths — 100/50 mcg, 250/50 mcg, and 500/50 mcg .
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in